Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

TARS – Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc.
TARS
$41.01
Name : Tarsus Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,723,002,240.00
EPSttm : -2.7
finviz dynamic chart for TARS
Tarsus Pharmaceuticals, Inc.
$41.01
1.64%
$0.66

Float Short %

22.38

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

0.29

EPS Last/This Y

1.83

EPS This/Next Y

0.81

Price

40.33

Target Price

72.43

Analyst Recom

1.29

Performance Q

-20.34

Relative Volume

1.19

Beta

0.81

Ticker: TARS




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02TARS43.810.230.00538
2025-06-03TARS43.890.230.00538
2025-06-04TARS42.60.230.00538
2025-06-05TARS44.050.230.00538
2025-06-06TARS43.840.220.71543
2025-06-09TARS43.110.2312.50548
2025-06-10TARS41.140.230.53548
2025-06-11TARS40.90.220.00563
2025-06-12TARS40.980.210.11583
2025-06-13TARS40.920.210.19593
2025-06-16TARS41.260.210.19593
2025-06-17TARS39.380.200.06618
2025-06-18TARS41.060.20999.99645
2025-06-20TARS40.330.20999.99646
2025-06-23TARS40.50.174.00506
2025-06-24TARS41.390.194.00518
2025-06-25TARS40.160.190.00517
2025-06-26TARS40.290.18999.99524
2025-06-27TARS40.320.190.00525
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02TARS43.8350.5- -1.24
2025-06-03TARS43.9150.5- -1.24
2025-06-04TARS42.6350.5- -1.24
2025-06-05TARS44.0850.5- -1.24
2025-06-06TARS43.8450.5- -1.24
2025-06-09TARS43.1150.5- -1.24
2025-06-10TARS41.1750.5- -1.24
2025-06-11TARS40.9250.5- -1.24
2025-06-12TARS40.9550.5- -1.24
2025-06-13TARS40.9050.5- -1.24
2025-06-16TARS41.2250.5- -1.24
2025-06-17TARS39.3850.5- -1.24
2025-06-18TARS41.0750.5- -1.24
2025-06-20TARS40.6550.5- -1.24
2025-06-23TARS40.5350.5- -1.24
2025-06-24TARS41.3850.5- -1.24
2025-06-25TARS40.1850.5- -1.24
2025-06-26TARS40.3750.5- -1.24
2025-06-27TARS40.3350.5- -1.24
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02TARS-1.179.9621.46
2025-06-03TARS-1.179.9621.46
2025-06-04TARS-1.179.9621.46
2025-06-05TARS-1.179.9621.46
2025-06-06TARS-1.179.9621.46
2025-06-09TARS-1.1710.0221.46
2025-06-11TARS-1.1710.0222.27
2025-06-12TARS-1.4710.0222.27
2025-06-13TARS-1.4710.0222.27
2025-06-16TARS-1.4710.0222.26
2025-06-17TARS-1.4910.0222.26
2025-06-18TARS-1.7210.0222.26
2025-06-19TARS-1.4910.0222.26
2025-06-20TARS-1.7210.0222.26
2025-06-24TARS-1.719.9822.28
2025-06-25TARS-1.719.9822.28
2025-06-26TARS-1.719.9822.38
2025-06-27TARS-1.719.9822.38
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.64

Avg. EPS Est. Current Quarter

-0.41

Avg. EPS Est. Next Quarter

-0.35

Insider Transactions

-1.71

Institutional Transactions

9.98

Beta

0.81

Average Sales Estimate Current Quarter

95

Average Sales Estimate Next Quarter

104

Fair Value

Quality Score

48

Growth Score

57

Sentiment Score

82

Actual DrawDown %

36.7

Max Drawdown 5-Year %

Target Price

72.43

P/E

Forward P/E

33.07

PEG

P/S

7.25

P/B

4.95

P/Free Cash Flow

EPS

-2.73

Average EPS Est. Cur. Y​

-1.24

EPS Next Y. (Est.)

-0.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-44.91

Relative Volume

1.19

Return on Equity vs Sector %

-54.5

Return on Equity vs Industry %

-36.7

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.25

EBIT Estimation

Tarsus Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 323
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
stock quote shares TARS – Tarsus Pharmaceuticals Inc Stock Price stock today
news today TARS – Tarsus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch TARS – Tarsus Pharmaceuticals Inc yahoo finance google finance
stock history TARS – Tarsus Pharmaceuticals Inc invest stock market
stock prices TARS premarket after hours
ticker TARS fair value insiders trading